Moderna reported that its cytomegalovirus (CMV) mRNA vaccine missed primary efficacy goals in a Phase 3 study and the company will stop most development of the program. The firm said efficacy was “well below” expectations in the late-stage readout, prompting management to scale back the asset and reallocate resources across its vaccine portfolio. The outcome removes a previously forecast blockbuster from Moderna’s pipeline and piles pressure on its broader respiratory and congenital-virus vaccine strategy. The company briefed investors and the market cited analyst notes that the result will weigh on near-term revenue expectations and raise questions about mRNA platform performance for some prophylactic indications. Regulators were not cited in the initial communications; Moderna said it will update stakeholders on next steps. Investors and competitors will watch for further company guidance on pipeline prioritization and whether data from the failed study yield mechanistic insights that could inform other mRNA programs.